iMedicor Launches Phase I Product Marketing Program for MuGard

NANUET, N.Y.--(BUSINESS WIRE)--iMedicor (OTCBB: VMCI) today announced its launch of Access Pharmaceuticals’ MuGard product through its pharma online marketing portal, ClearLobby, and its direct sales channel, Direct Medical Solutions (DMS). The initial phase of the marketing program includes a targeted MuGard sampling program to select iMedicor users and the DMS’ physician network. As previously announced, iMedicor has been selected by Access Pharmaceuticals, Inc. (OTCBB: ACCP) to support the North American commercial launch efforts of its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis and stomatitis, a debilitating side effect of radiotherapy and/or chemotherapy.

Back to news